Teva Inks $450m Deals Over US Kickback Claims, Including For Generic Price-Fixing

Eight-Figure Payment In Addition To $225m Criminal Penalty Imposed On Teva Last Year

Teva has resolved a pair of civil US Department of Justice lawsuits accusing the firm of violating the US Anti-Kickback Statute and the False Claims Act through its alleged conduct conspiring to fix the price of three generic drugs and for allegedly paying Medicare patients’ copays for its multiple sclerosis brand Copaxone.

Settlement newspaper headline on money
• Source: Shutterstock

The US Department of Justice noted that total recoveries pertaining to allegations of generic price fixing have exceeded $500m, after Teva became the seventh company to settle civil claims for its alleged involvement in a pricing conspiracy for three drugs, including pravastatin.

The Israeli firm has agreed to pay $25m to settle allegations that it violated sections of the Anti-Kickback Statue by conspiring with other manufacturers to fix prices and/or allocate markets for the widely-used statin,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Gedeon Richter: General Medicines Unit Deserves ‘More Attention And Credit’

 
• By 

Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By 

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.